TY - JOUR
T1 - Phase I clinical trial of CEP-2563 dihydrochloride, a receptor tyrosine kinase inhibitor, in patients with refractory solid tumors
AU - Undevia, Samir D.
AU - Vogelzang, Nicholas J.
AU - Mauer, Ann M.
AU - Janisch, Linda
AU - Mani, Sridhar
AU - Ratain, Mark J.
N1 - Copyright:
Copyright 2012 Elsevier B.V., All rights reserved.
PY - 2004/11
Y1 - 2004/11
N2 - CEP-2563 dihydrochloride (CEP-2563) is a soluble lysinyl-β-alanyl ester of CEP-751, a potent inhibitor of the trk family of receptor tyrosine kinases and the platelet-derived growth factor (PDGF) receptor tyrosine kinase. CEP-2563 was developed because of the limited aqueous solubility of CEP-751. Preclinical models have demonstrated that both CEP-751 and CEP-2563 have antitumor activity in a variety of tumors. A Phase I clinical trial involving 18 patients was conducted to determine the toxicity profile, maximum tolerated dose (MTD), toxicity profile, and pharmacokinetics of CEP-2563 in patients with advanced solid tumors refractory to standard therapy. CEP-2563 was administered over 1 hour via a central venous catheter once daily for five consecutive days every three weeks. A rapid dose titration strategy with initial single patient cohorts and 100% dose escalations was used. With the appearance of drug-related toxicity, escalations were decreased to 50% or 25% and cohorts were expanded to 3 or 6 patients until establishment of the MTD. Dose escalation rapidly proceeded to 320 mg/m 2/d. The dose limiting toxicities (DLTs) observed were grade 3 hypotension and grade 2 allergic reaction. Other toxicities included anemia, thrombocytopenia, anorexia, asthenia, diarrhea, fatigue, headache, nausea, vomiting, and rash. Pharmacokinetic analysis showed that CEP-2563 is reliably converted to CEP-751. This study demonstrated that single agent CEP-2563 therapy is feasible with acceptable toxicities. The recommended phase II dose is 256 mg/m 2/d. Rapid dose escalation with single patient cohorts was a safe and efficient method of conducting this phase I trial.
AB - CEP-2563 dihydrochloride (CEP-2563) is a soluble lysinyl-β-alanyl ester of CEP-751, a potent inhibitor of the trk family of receptor tyrosine kinases and the platelet-derived growth factor (PDGF) receptor tyrosine kinase. CEP-2563 was developed because of the limited aqueous solubility of CEP-751. Preclinical models have demonstrated that both CEP-751 and CEP-2563 have antitumor activity in a variety of tumors. A Phase I clinical trial involving 18 patients was conducted to determine the toxicity profile, maximum tolerated dose (MTD), toxicity profile, and pharmacokinetics of CEP-2563 in patients with advanced solid tumors refractory to standard therapy. CEP-2563 was administered over 1 hour via a central venous catheter once daily for five consecutive days every three weeks. A rapid dose titration strategy with initial single patient cohorts and 100% dose escalations was used. With the appearance of drug-related toxicity, escalations were decreased to 50% or 25% and cohorts were expanded to 3 or 6 patients until establishment of the MTD. Dose escalation rapidly proceeded to 320 mg/m 2/d. The dose limiting toxicities (DLTs) observed were grade 3 hypotension and grade 2 allergic reaction. Other toxicities included anemia, thrombocytopenia, anorexia, asthenia, diarrhea, fatigue, headache, nausea, vomiting, and rash. Pharmacokinetic analysis showed that CEP-2563 is reliably converted to CEP-751. This study demonstrated that single agent CEP-2563 therapy is feasible with acceptable toxicities. The recommended phase II dose is 256 mg/m 2/d. Rapid dose escalation with single patient cohorts was a safe and efficient method of conducting this phase I trial.
KW - CEP-2563
KW - maximum tolerated dose
KW - pharmacokinetics
KW - phase I clinical trial
KW - toxicity
UR - http://www.scopus.com/inward/record.url?scp=10244241837&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=10244241837&partnerID=8YFLogxK
U2 - 10.1023/B:DRUG.0000036687.26604.8c
DO - 10.1023/B:DRUG.0000036687.26604.8c
M3 - Article
C2 - 15292715
AN - SCOPUS:10244241837
SN - 0167-6997
VL - 22
SP - 449
EP - 458
JO - Investigational New Drugs
JF - Investigational New Drugs
IS - 4
ER -